絞り込み

16645

広告

自己肯定感がねじれてる

高校卒業して、20代前半はずっと深夜のコンビニバイトしていた。(月20万弱) このままじゃいけないと思って全くの別業界にバイトチェンジした。 右も左も何もわから...

  1. 新しい下水処理システムが全国へ (デイリ...
  2. [医学] 急性骨髄性白血病治療の根幹薬シ...
  3. オリオン座が崩れる? ベテルギウスに異変...
  4. 生物の時間スケールはガラスに似た仕組みで...

ニュース一覧

「"Barco S "[Author]」の検索結果

141件中 121件~140件表示    検索結果をPubMedで見る PubMedで見る

Metformin: Multi-faceted protection against cancer.

Erythrocyte Galactose-1-phosphate measurement by GC-MS in the monitoring of classical galactosemia.

Repositioning chloroquine and metformin to eliminate cancer stem cell traits in pre-malignant lesions.

Micro(mi)RNA expression profile of breast cancer epithelial cells treated with the anti-diabetic drug metformin: Induction of the tumor suppressor miRNA let-7a and suppression of the TGFβ-induced oncomiR miRNA-181a.

Circulating fatty acid synthase: an exploratory biomarker to predict efficacy of the dual HER1/HER2 tyrosine kinase inhibitor lapatinib.

Expression status of the autophagy-regulatory gene ATG6/BECN1 in ERBB2-positive breast carcinomas: Bypassing ERBB2-induced oncogenic senescence to regulate the efficacy of ERBB2-targeted therapies.

Phase I/II study of biweekly vinorelbine and oxaliplatin as first-line treatment in patients with metastatic breast cancer.

The anti-diabetic drug metformin suppresses the metastasis-associated protein CD24 in MDA-MB-468 triple-negative breast cancer cells.

Metformin regulates breast cancer stem cell ontogeny by transcriptional regulation of the epithelial-mesenchymal transition (EMT) status.

Pathway-focused proteomic signatures in HER2-overexpressing breast cancer with a basal-like phenotype: New insights into de novo resistance to trastuzumab (Herceptin).

Lapatinib, a dual HER1/HER2 tyrosine kinase inhibitor, augments basal cleavage of HER2 extracellular domain (ECD) to inhibit HER2-driven cancer cell growth.

Dynamic emergence of the mesenchymal CD44(pos)CD24(neg/low) phenotype in HER2-gene amplified breast cancer cells with De novo resistance to trastuzumab (Herceptin).

The anti-diabetic drug metformin suppresses self-renewal and proliferation of trastuzumab-resistant tumor-initiating breast cancer stem cells.

Fatty acid synthase activity regulates HER2 extracellular domain shedding into the circulation of HER2-positive metastatic breast cancer patients.

If mammalian target of metformin indirectly is mammalian target of rapamycin, then the insulin-like growth factor-1 receptor axis will audit the efficacy of metformin in cancer clinical trials.

mTOR inhibitors and the anti-diabetic biguanide metformin: new insights into the molecular management of breast cancer resistance to the HER2 tyrosine kinase inhibitor lapatinib (Tykerb).

The antidiabetic drug metformin: a pharmaceutical AMPK activator to overcome breast cancer resistance to HER2 inhibitors while decreasing risk of cardiomyopathy.

Phase II study of oral vinorelbine in combination with carboplatin followed by consolidation therapy with oral vinorelbine as single-agent in unresectable localized or metastatic non-small cell lung carcinoma.

Growth and molecular interactions of the anti-EGFR antibody cetuximab and the DNA cross-linking agent cisplatin in gefitinib-resistant MDA-MB-468 cells: new prospects in the treatment of triple-negative/basal-like breast cancer.

  1. 3
  2. 4
  3. 5
  4. 6
  5. 7
  6. 8
Sort by
※並べ替えは表示に時間がかかります